Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
Objectives This study aimed to analyse the cost–utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand.Design Economic evaluation using a decision-analytical model.Setting Thailand.Participants...
Saved in:
Main Authors: | Nitichen Kittiratchakool, Disorn Kulpokin, Chonticha Chanjam, Soamarat Vilaiyuk, Sirirat Charuvanij, Gun Phongsamart, Parichat Khaosut, Manasita Tanya, Ratanavadee Nanagara, Sira Nantapaisarn, Pattara Leelahavarong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-09-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/9/e037588.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand
by: Natthakan Chitpim, et al.
Published: (2025-01-01) -
Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
by: Yong Wang, et al.
Published: (2022-01-01) -
COVID-19 Induced Cardiomyopathy Successfully Treated with Tocilizumab
by: Ariyon Schreiber, et al.
Published: (2022-01-01) -
Lack of efficacy of tocilizumab in acute exacerbation of pulmonary fibrosis
by: Giovanni Franco, et al.
Published: (2024-12-01) -
Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis
by: Phorntida Hadnorntun, et al.
Published: (2025-01-01)